Please assess the completion status of the following clinical trial:

Trial Title: The Norwegian Tenecteplase Stroke Trial 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
General inclusion criteria~* 18 years or older~* Ischaemic stroke with clinical symptoms corresponding to National Institutes of Health Stroke Scale Score (NIHSS) of \>5. All stroke sub-types and vascular distributions are eligible. A visible arterial occlusion is not required for inclusion.~* Treatment \<4½ hours after stroke onset or after awakening with symptoms.~* Informed consent by patient or by patient's family~Specific sub-set inclusion criteria~* Wake-Up Stroke: FLAIR-DWI mismatch on MRI as judged by the (neuro-) radiologist or neurologist.~* Thrombectomy: Occlusion of intracerebral artery technically accessible for endovascular embolectomy as defined by local treatment protocols.~Exclusion criteria~* Prestroke modified rankin scale of ≥3~* Large areas of hypodense ischaemic changes on baseline CT;~* Patients with systolic blood pressure \>185 mm Hg or diastolic blood pressure \>110 mm Hg in spite of acute antihypertensive treatment;~* Pregnant women (are treated with alteplase);~* Women with possible pregnancy (are treated with alteplase)~* Beast feeding women, if a 24 hours stop of feeding is not feasible.~* Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is normal;~* Known bleeding diathesis; use of oral anticoagulants with no antidot, INR ≥1,4; heparin \<48 hours and increased APTT; low molecular weight heparin(oid) \<24 hours; another investigational drug \<14 days;~* Patients with arterial puncture at a noncompressible site or lumbar puncture \<7 days; major surgery or serious trauma \<14 days; gastrointestinal or urinary tract hemorrhage \<14 days; clinical stroke \<2 months; history of intracranial haemorrhage; CNS neurosurgery \<2 months; serious head trauma \<2 months; pericarditis; sepsis; any serious medical illness likely to interact with treatment; confounding pre-existent neurological or psychiatric disease; unlikely to complete follow-up;~* Any condition that, in the opinion of the investigator, puts a patient at risk if treated with thrombolysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenecteplase (Type: ACTIVE_COMPARATOR): Tenecteplase
- Alteplase (Type: ACTIVE_COMPARATOR): Alteplase

Based on this trial design, predict the completion outcome and termination type (if applicable).